Yong (Tiger) Zhang

Yong (Tiger) Zhang, PhD

Assistant Professor

Pharmacology and Pharmaceutical SciencesCurriculum Vitae

Research Topics

  1. Chemical Biology
  2. Drug Design and Discovery
  3. Antibody Engineering
  4. Immunotherapy
  5. Enzymology
  6. Protein Biosynthesis
  7. Cancer, Diabetes and Neurodegeneration

Contact Information

  • Web Sites
  • yongz@usc.edu
  • USC School of Pharmacy
    University of Southern California
    1985 Zonal Ave.
    PSC 606
    Los Angeles, CA 90089-9121
  • PSC 606
  • (323) 442-1405
  • PSC 605 & 610
  • (323) 224-7473

Education

B.S. 2003 Biological Sciences - Shandong University, China
M.S. 2006 Biophysics - University of Guelph, Canada
Ph.D. 2011 Biochemistry - Albert Einstein College of Medicine, Bronx, NY

Postdoctoral 2011-2014 - The Scripps Research Institute; California Institute for Biomedical Research, La Jolla, CA

Yong (Tiger) Zhang

Research Interest

Protein post-translational modifications (PTMs) result in critical changes on protein structure and biological function. The broad range of PTMs observed on various proteins vastly diversifies the inventory of organism proteome. Furthermore, highly abundant PTMs with dynamic pattern play essential and complex roles in biological processes. Our laboratory is very interested in developing innovative technologies to systematically dissect PTMs essential for cancer, inflammation, neurodegeneration and immune disorders for understanding the functional consequences and regulatory mechanisms of PTMs and for discovery of novel therapeutic targets and drug inhibitors.

Antibody recognizes and neutralizes foreign pathogens and is an important component in immune system. The exquisite specificity and tight-binding affinity of monoclonal antibodies make antibody-based therapeutics ideal drug candidates. Development of monoclonal antibodies against ligands, receptors, and protein-protein interactions that play critical roles in various human diseases allows discovery of powerful therapeutic agents with minimum off-target effects. We are aimed at designing potent monoclonal antibodies with high specificity as novel immunotherapeutic tools for cancer, immune disorders, neurodegenerative, and infectious diseases, and developing new and robust protein engineering approaches for efficient generation of potent polypeptide-based diagnostics and therapeutics.

Graduate students can receive direct and extensive training from PI in antibody engineering, enzymology and catalysis, inhibitor design and synthesis, protein expression, purification and characterization, cell culturing, assay development, proteomics, X-ray crystallography and NMR, pharmacokinetics and pharmacodynamics, and high-throughput screening. Upon graduation, students are expected to possess multiple sets of skills and strong publication record, essential for career development in both academia and industry.

Biography

Dr. Zhang received his B.S. in Biological Sciences from Shandong University in 2003 and his M.S. in Biophysics from University of Guelph in 2006. He earned his Ph.D. in Biochemistry with Professor Vern L. Schramm at Albert Einstein College of Medicine in 2011. His doctoral research was focused on the enzymatic transition state and catalytic mechanism for rational design of potent enzyme inhibitors as antimalarial and anticancer drugs. Dr. Zhang received postdoctoral training with Professor Peter G. Schultz at the Scripps Research Institute and California Institute for Biomedical Research (Calibr) from 2011 to 2014. His postdoctoral work established a versatile approach to the generation of novel antibody chimeras with excellent physical, biological, and pharmacological properties for drug development. Dr. Zhang joined the faculty in the Department of Pharmacology and Pharmaceutical Sciences at USC School of Pharmacy as an Assistant Professor in December 2014.

Selected Projects/Publications

View a complete PubMed search

Liu, T., Zhang, Y. (co-first author), Liu, Y., Wang, Y., Jia, H., Kang, M., Luo, X., Caballero, D., Gonzalez, J., Wang, D., Woods, A., Schultz, P.G. and Wang, F. Functional Human Antibody CDR Fusions as Long-Acting Therapeutic Endocrine Agonists. Proc. Natl. Acad. Sci. U.S.A., In Press -Link

Zhang, Y., Zou, H., Wang, Y., Caballero, D., Gonzalez, J., Chao, E., Welzel, G., Shen, W., Wang, D., Schultz, P.G. and Wang, F. Rational Design of a Humanized Glucagon-Like Peptide-1 Receptor Agonist Antibody. Angew. Chem. Int. Ed. Engl., In Press -Link

Zhang, Y. (co-first author), Liu, Y., Wang, Y., Schultz, P.G. and Wang, F. Rational Design of Humanized Dual-Agonist Antibodies. J. Am. Chem. Soc., In Press -Link

Zhang, Y., Goswami, D., Wang, D., Wang, T.S.A., Sen, S., Magliery, T.J., Griffin, P.R., Wang, F. and Schultz, P.G. An Antibody with a Variable Region Coiled-Coil “Knob” Domain. Angew. Chem. Int. Ed. Engl., 2014, 53, 132-135. -Link

Zhang, Y., Evans, G.B., Clinch, K., Crump, D.R., Harris, L.D., Fröhlich, R.F.G., Tyler, P.C., Hazleton, K.Z., Cassera, M.B. and Schramm, V.L. Transition State Analogues of Plasmodium falciparum and Human Orotate Phosphoribosyltransferases. J. Biol. Chem., 2013, 288, 34746-54 -Link

Zhang, Y., Wang, D., Welzel, G., Wang, Y., Schultz, P.G. and Wang, F. An Antibody CDR3-Erythropoietin Fusion Protein. ACS Chem. Biol., 2013, 8, 2117-2121 -Link

Zhang, Y., Wang, D., de Lichtervelde, L., Sun, S.B., Smider, V.V., Schultz, P.G. and Wang, F. Functional Antibody CDR3 Fusion Proteins with Enhanced Pharmacological Properties. Angew. Chem. Int. Ed. Engl., 2013, 52, 8295-8298 -Link

Wang, F., Ekiert, D.C., Ahmad, I., Li, W., Zhang, Y., Bazirgan, O., Torkamani, A., Raudsepp, T., Mwangi, W., Criscitiello, M.F., Wilson, I.A., Schultz, P.G. and Smider. V.V. Reshaping Antibody Diversity. Cell, 2013, 153, 1379-93 -Link

Wang, F., Sen, S., Zhang, Y., Ahmad, I., Zhu, X., Wilson, I.A., Smider, V.V., Magliery, T.J. and Schultz, P.G. Somatic Hypermutation Maintains Antibody Thermodynamic Stability During Affinity Maturation. Proc. Natl. Acad. Sci. U.S.A., 2013,110, 4261-4266 -Link

Zhang, Y., Deng, H. and Schramm, V.L. Leaving Group Activation and Pyrophosphate Ionic State at the Catalytic Site of Plasmodium falciparum Orotate Phosphoribosyltransferase. J. Am. Chem. Soc., 2010, 132, 17023-17031 -Link

Zhang, Y. and Schramm, V.L. Pyrophosphate Interactions at the Transition States of Plasmodium falciparum and Human Orotate Phosphoribosyltransferases. J. Am. Chem. Soc., 2010, 132, 8787-8794 -Link

Zhang, Y., Luo, M. and Schramm, V.L. Transition States of Plasmodium falciparum and Human Orotate Phosphoribosyltransferases. J. Am. Chem. Soc., 2009, 131, 4685-4694 -Link